Argatroban dosing requirements in extracorporeal life support and other critically ill populations

Argatroban is a parenteral direct thrombin inhibitor that requires close monitoring to ensure safety and efficacy. Limited data exist to describe its effect in critically ill patients. This was a retrospective, single-center, cohort study that aimed to compare argatroban dosing requirements in those receiving extracorporeal life support (ECLS), continuous renal replacement therapy (CRRT), or neither. Organ dysfunction was assessed using a modified version of the Sequential Organ Failure Assessment (modSOFA) that incorporated the use of extracorporeal support systems.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Full Length Article Source Type: research
More News: Hematology | Study | Thrombosis